P. Vasey

5.5k total citations · 1 hit paper
97 papers, 3.8k citations indexed

About

P. Vasey is a scholar working on Oncology, Reproductive Medicine and Surgery. According to data from OpenAlex, P. Vasey has authored 97 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 44 papers in Reproductive Medicine and 39 papers in Surgery. Recurrent topics in P. Vasey's work include Ovarian cancer diagnosis and treatment (44 papers), Intraperitoneal and Appendiceal Malignancies (16 papers) and Cancer Treatment and Pharmacology (15 papers). P. Vasey is often cited by papers focused on Ovarian cancer diagnosis and treatment (44 papers), Intraperitoneal and Appendiceal Malignancies (16 papers) and Cancer Treatment and Pharmacology (15 papers). P. Vasey collaborates with scholars based in United Kingdom, Australia and France. P. Vasey's co-authors include Robert Brown, James Paul, A. Hay, Gillian M. Ross, Stan B. Kaye, Robert H. Jones, Hani Gabra, Stanley B. Kaye, Gordon C. Jayson and Stuart Kaye and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The Lancet Oncology.

In The Last Decade

P. Vasey

95 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

2010 410 citations Éric Pujade-Lauraine, Uwe Wagner et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by P. Vasey

Since Specialization

Citations

This map shows the geographic impact of P. Vasey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Vasey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Vasey more than expected).

Fields of papers citing papers by P. Vasey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Vasey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Vasey. The network helps show where P. Vasey may publish in the future.

Co-authorship network of co-authors of P. Vasey

This figure shows the co-authorship network connecting the top 25 collaborators of P. Vasey. A scholar is included among the top collaborators of P. Vasey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Vasey. P. Vasey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA108 Durvalumab (D) in combination with Bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): Final analysis of the phase III, open-label, randomised POTOMAC trial 2025 ·Annals of Oncology ·(unknown), Juan Palou, (unknown), M Krawczyński, (unknown), (unknown), (unknown), (unknown), Lieven Goeman, Eva Hellmis, Thomas Powles, (unknown), P. Vasey, P. Bigot, Yves Fradet, (unknown), (unknown), (unknown), (unknown), (unknown)	0
2	1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601) 2023 ·Annals of Oncology ·Craig Gedye, Carole A. Harris, Martin R. Stockler, (unknown), (unknown), Jeffrey C. Goh, Andrew Martin, Craig Underhill, David Pook, Laurence E. Krieger, Ganessan Kichenadasse, Abhishek Joshi, Shalini Subramaniam, (unknown), (unknown), Anthony M. Joshua, Guy C. Toner, P. Vasey, Prashanth Prithviraj, Ian D. Davis	0
3	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover 2020 ·Cancers ·Célèste Lebbé, Caroline Dutriaux, Thierry Lesimple, (unknown), Joseph Kerger, L. Thomas, B. Guillot, Filippo de Braud, Claus Garbe, Jean‐Jacques Grob, Carmen Loquai, Virginia Ferraresi, Caroline Robert, P. Vasey, Robert M. Conry, Richard Isaacs, Enrique Espinosa, Armin Schueler, (unknown), Brigitte Dréno	32
4	Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) 2013 ·Annals of Oncology ·Peter Grimison, Martin R. Stockler, Mark D. Chatfield, D. B. Thomson, Val Gebski, Michael Friedländer, (unknown), Baerin Houghton, Howard Gurney, Mark Rosenthal, Nimit Singhal, Ganessan Kichenadasse, Stanley Sau Ching Wong, Craig Lewis, P. Vasey, Guy C. Toner	31
5	Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a Phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial 2013 ·European Journal of Cancer ·Michael Aitchison, Caroline A. Bray, Hendrik Van Poppel, Richard Sylvester, John D. Graham, (unknown), Lynn McMahon, P. Vasey	30
6	A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG 2012 ·Annals of Oncology ·Susana Banerjee, (unknown), James Paul, Christopher J.M. Williams, (unknown), Hani Gabra, G. Skailes, Alan Lamont, Andrew Hindley, Greg G. Goss, Edward D. Gilby, Martin Hogg, Peter Harper, Emma Kipps, Liz-Anne Lewsley, Marcia Hall, P. Vasey, Stuart Kaye	31
7	Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse breakdown → 2010 ·Journal of Clinical Oncology ·Éric Pujade-Lauraine, Uwe Wagner, (unknown), Val Gebski, M. Heywood, P. Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero, Jalid Sehouli, Alain Lortholary, Gunnar B. Kristensen, Christian Jackisch, Florence Joly, Chris Brown, Nathalie Le Fur, Andreas du Bois	410
8	18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: Preliminary report of MRC trial TE22 - The NCRI testis tumour clinical study group 2007 ·UCL Discovery (University College London) ·Robert Huddart, (unknown), Anwar R. Padhani, (unknown), G.M. Mead, (unknown), P. Vasey, (unknown), Jennifer Logue, Gedske Daugaard, (unknown), (unknown), (unknown), (unknown)	5
9	¹⁸ Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22—The NCRI Testis Tumour Clinical Study Group 2007 ·Journal of Clinical Oncology ·Robert Huddart, Michael O’Doherty, Anwar R. Padhani, Gordon Rustin, Graham M. Mead, Johnathan Joffe, P. Vasey, Stephen Harland, John Logue, Gedske Daugaard, Sharon F. Hain, S Kirk, Jane E. Mackewn, Sally Stenning	68
10	Integration of new or experimental treatment options and new approaches to clinical trials 2005 ·Annals of Oncology ·Michael Quinn, Jacobus Pfisterer, (unknown), Michael A. Bookman, David D.L. Bowtell, Antonio Casado, Andrés Cervantes, Seija Grénman, (unknown), Amit M. Oza, S. Pecorelli, Éric Pujade-Lauraine, Edward L. Trimble, P. Vasey, Uwe Wagner	2
11	"Dose dense" chemotherapy in ovarian cancer 2005 ·International Journal of Gynecological Cancer ·P. Vasey	9
12	Octreotide: an active agent in epithelial ovarian carcinoma? 2004 ·The Lancet Oncology ·Robert H. Jones, Jean–Claude Reubi, David Millan, P. Vasey	7
13	Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma 2004 ·JNCI Journal of the National Cancer Institute ·P. Vasey, Gordon C. Jayson, Amanda Gordon, Hani Gabra, Robert L. Coleman, R. Atkinson, David E. Parkin, J. P. Paul, A. Hay, Stuart Kaye, (unknown)	446
14	A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer 2003 ·British Journal of Cancer ·P. Vasey, Lynn McMahon, James Paul, Nicholas Reed, Stan B. Kaye	22
15	A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma 2003 ·British Journal of Cancer ·(unknown), Fiona Blackhall, P. Vasey, M Soukop, Robert E. Coleman, Gavin Halbert, L Robson, Gordon C. Jayson	33
16	A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer 2002 ·British Journal of Cancer ·V J O'Neill, S.B. Kaye, Nicholas Reed, James Paul, Jo Ann Davis, P. Vasey	6
17	New directions in testicular cancer; molecular determinants of oncogenesis and treatment success 2002 ·European Journal of Cancer ·Robert H. Jones, P. Vasey	31
18	A Pilot Study of Continuous Infusional 5-Fluorouracil, Doxorubicin and Cyclophosphamide in Breast Cancer 1999 ·Clinical Oncology ·Helen Mackay, D. Bissett, Chris Twelves, P. Vasey	1
19	Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. 1996 ·Molecular Pharmacology ·P. Vasey, Neil A. Jones, Suzanne Jenkins, Caroline Dive, Robert Brown	96
20	Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy 1994 ·Annals of Oncology ·P. Vasey, David J. Dunlop, S.B. Kaye	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact